Atria Investments LLC Grows Stock Position in Johnson & Johnson (NYSE:JNJ)

Atria Investments LLC raised its position in Johnson & Johnson (NYSE:JNJGet Rating) by 2.7% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 169,599 shares of the company’s stock after purchasing an additional 4,538 shares during the quarter. Atria Investments LLC’s holdings in Johnson & Johnson were worth $30,058,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of JNJ. Riversedge Advisors LLC raised its holdings in shares of Johnson & Johnson by 8.6% in the 4th quarter. Riversedge Advisors LLC now owns 3,664 shares of the company’s stock worth $627,000 after purchasing an additional 289 shares during the period. Andrew Hill Investment Advisors Inc. acquired a new stake in shares of Johnson & Johnson in the fourth quarter valued at about $3,435,000. Ascent Wealth Partners LLC grew its stake in shares of Johnson & Johnson by 2.3% in the fourth quarter. Ascent Wealth Partners LLC now owns 28,855 shares of the company’s stock valued at $4,936,000 after buying an additional 651 shares in the last quarter. PFG Private Wealth Management LLC acquired a new stake in Johnson & Johnson during the 4th quarter valued at approximately $99,000. Finally, First Merchants Corp grew its stake in Johnson & Johnson by 4.2% during the 4th quarter. First Merchants Corp now owns 59,341 shares of the company’s stock valued at $10,151,000 after purchasing an additional 2,383 shares in the last quarter. 68.78% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Johnson & Johnson

In related news, EVP Kathryn E. Wengel sold 40,000 shares of Johnson & Johnson stock in a transaction on Friday, June 10th. The stock was sold at an average price of $173.00, for a total value of $6,920,000.00. Following the transaction, the executive vice president now directly owns 71,311 shares in the company, valued at approximately $12,336,803. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, EVP Kathryn E. Wengel sold 40,000 shares of Johnson & Johnson stock in a transaction on Friday, June 10th. The stock was sold at an average price of $173.00, for a total value of $6,920,000.00. Following the transaction, the executive vice president now directly owns 71,311 shares in the company, valued at approximately $12,336,803. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CAO Robert J. Decker sold 8,462 shares of Johnson & Johnson stock in a transaction on Thursday, May 26th. The stock was sold at an average price of $180.00, for a total value of $1,523,160.00. Following the completion of the transaction, the chief accounting officer now owns 15,473 shares in the company, valued at $2,785,140. The disclosure for this sale can be found here. Company insiders own 0.35% of the company’s stock.

Johnson & Johnson Stock Down 0.3 %

Shares of Johnson & Johnson stock opened at $173.20 on Thursday. The business’s fifty day moving average price is $175.99 and its two-hundred day moving average price is $174.36. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.39 and a quick ratio of 1.14. The company has a market capitalization of $455.76 billion, a P/E ratio of 25.21, a PEG ratio of 3.28 and a beta of 0.63. Johnson & Johnson has a 1-year low of $155.72 and a 1-year high of $186.69.

Johnson & Johnson (NYSE:JNJGet Rating) last posted its quarterly earnings data on Tuesday, July 19th. The company reported $2.59 EPS for the quarter, topping analysts’ consensus estimates of $2.57 by $0.02. Johnson & Johnson had a return on equity of 36.56% and a net margin of 19.21%. The company had revenue of $24.02 billion for the quarter, compared to the consensus estimate of $23.85 billion. During the same quarter in the previous year, the business earned $2.48 EPS. The company’s quarterly revenue was up 3.0% compared to the same quarter last year. As a group, research analysts forecast that Johnson & Johnson will post 10.05 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 6th. Stockholders of record on Tuesday, August 23rd will be paid a $1.13 dividend. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.61%. The ex-dividend date is Monday, August 22nd. Johnson & Johnson’s dividend payout ratio is presently 65.79%.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on JNJ. Raymond James raised their price objective on Johnson & Johnson from $195.00 to $196.00 and gave the company an “outperform” rating in a research note on Wednesday, April 20th. UBS Group lowered their price objective on Johnson & Johnson from $185.00 to $180.00 in a research note on Thursday, July 21st. Daiwa Capital Markets started coverage on Johnson & Johnson in a research report on Wednesday, June 22nd. They issued an “outperform” rating for the company. Credit Suisse Group lifted their target price on Johnson & Johnson from $200.00 to $205.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 20th. Finally, Morgan Stanley lifted their target price on Johnson & Johnson from $173.00 to $174.00 and gave the stock an “equal weight” rating in a research report on Friday, July 8th. Four research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $189.89.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Read More

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).



Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *